Advertisement

Natriuretic Peptides

  • Massimo VolpeEmail author
  • Speranza Rubattu
Chapter
Part of the Updates in Hypertension and Cardiovascular Protection book series (UHCP)

Abstract

The cardiac natriuretic peptides (NPs) family comprises three main peptides (ANP, BNP and CNP) which are provided with properties relevant for cardiovascular and fluid homeostasis. They produce their cardiovascular and renal effects through the binding with guanylyl cyclase (GC)-coupled receptors, namely NPR-A and NPR-B. The NPR-C and neutral endopeptidase (NEP) contribute to NPs clearance. NPs levels progressively increase in heart failure (HF), in parallel with deterioration of left ventricular function and increased cardiac wall stress. The marked involvement of NPs in HF makes them valuable diagnostic and prognostic biomarkers. In view of their therapeutic implications in HF, inhibition of NPs catabolism through NEP has been obtained with the development of ARNi which comprises Angiotensin II-AT1 receptor blocker (valsartan) and a NEP inhibitor (sacubitril). ARNi has been recently introduced for the treatment of HF with reduced ejection fraction.

Keywords

ANP BNP CNP Guanylyl cyclase receptors NPR-C NEP ARNi 

References

  1. 1.
    Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol. 2009;191:341–66.CrossRefGoogle Scholar
  2. 2.
    Gardner DG, Deschepper CF, Ganong WF, Hane S, Fiddes J, Baxter JD, Lewicki J. Extra-atrial expression of the gene for atrial natriuretic factor. Proc Natl Acad Sci U S A. 1986;83:6697–701.CrossRefGoogle Scholar
  3. 3.
    de Bold AJ, Bruneau BG, Kuroski de Bold ML. Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res. 1996;31:7–18.CrossRefGoogle Scholar
  4. 4.
    Saxenhofer H, Raselli A, Weidmann P, Forssmann WG, Bub A, Ferrari P, Shaw SG. Urodilatin, a natriuretic factor from kidneys, can modify renal and cardiovascular function in men. Am J Phys. 1990;259(5 Pt 2):F832–8.Google Scholar
  5. 5.
    Schweitz H, Vigne P, Moinier D, Frelin C, Lazdunski M. A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J Biol Chem. 1992;267:13928–32.PubMedGoogle Scholar
  6. 6.
    Chen S, Cao P, Dong N, Peng J, Zhang C, Wang H, Zhou T, Yang J, Zhang Y, Martelli EE, Naga Prasad SV, Miller RE, Malfait AM, Zhou Y, Wu Q. PCSK6-mediated corin activation is essential for normal blood pressure. Nat Med. 2015;21:1048–53.CrossRefGoogle Scholar
  7. 7.
    Ichiki T, Huntley BK, Sangaralingham SJ, Burnett JC Jr. Pro-atrial natriuretic peptide: a novel guanylyl cyclase-A receptor activator that goes beyond atrial and B-type natriuretic peptides. JACC Heart Fail. 2015;3:715–23.CrossRefGoogle Scholar
  8. 8.
    Vesely DL. Atrial natriuretic hormones originating from the N-terminus of the atrial natriureticfactor prohormone. Clin Exp Pharmacol Physiol. 1995;22:108–14.CrossRefGoogle Scholar
  9. 9.
    Anand-Srivastava MB. Natriuretic peptide receptor-C signaling and regulation. Peptides. 2005;26:1044–59.CrossRefGoogle Scholar
  10. 10.
    Rubattu S, Sciarretta S, Morriello A, Calvieri C, Battistoni A, Volpe M. NPR-C: a component of the natriuretic peptide family with implications in human diseases. J Mol Med. 2010;88:889–97.CrossRefGoogle Scholar
  11. 11.
    Sciarretta S, Marchitti S, Bianchi F, Moyes A, Barbato E, Di Castro S, Stanzione R, Cotugno M, Castello L, Calvieri C, Eberini I, Sadoshima J, Hobbs AJ, Volpe M, Rubattu S. The C2238 atrial natriuretic peptide molecular variant is associated with endothelial damage and dysfunction through natriuretic peptide receptor C signaling. Circ Res. 2013;112:1355–64.CrossRefGoogle Scholar
  12. 12.
    Turner AJ, Brown CD, Carson JA, Barnes K. The neprilysin family in health and disease. Adv Exp Med Biol. 2000;477:229–40.CrossRefGoogle Scholar
  13. 13.
    Melo LG, Steinhelper ME, Pang SC, Tse Y, Ackermann U. ANP in regulation of arterial pressure and fluid-electrolyte balance: lessons from genetic mouse models. Physiol Genomics. 2000;3:45–58.CrossRefGoogle Scholar
  14. 14.
    Laragh JH. Atrial natriuretic hormone, the renin-aldosterone axis, and blood pressure-electrolyte homeostasis. N Engl J Med. 1985;313:1330–40.CrossRefGoogle Scholar
  15. 15.
    Volpe M. Atrial natriuretic peptide and the baroreflex control of circulation. Am J Hypertens. 1992;5:488–93.CrossRefGoogle Scholar
  16. 16.
    Volpe M, Cuocolo A, Vecchione F, Mele AF, Condorelli M, Trimarco B. Vagal mediation of the effects of atrial natriuretic factor on blood pressure and arterial baroreflexes in the rabbit. Circ Res. 1987;60:747–55.CrossRefGoogle Scholar
  17. 17.
    Kuhn M. Endothelial actions of atrial and B-type natriuretic peptides. Br J Pharmacol. 2012;166:522–31.CrossRefGoogle Scholar
  18. 18.
    Kathiresan S, Gona P, Larson MG, Vita JA, Mitchell GF, Tofler GH, Levy D, Newton-Cheh C, Wang TJ, Benjamin EJ, Vasan RS. Cross-sectional relations of multiple biomarkers from distinct biological pathways to brachial artery endothelial function. Circulation. 2006;113:938–45.CrossRefGoogle Scholar
  19. 19.
    Rubattu S, Sciarretta S, Valenti V, Stanzione R, Volpe M. Natriuretic peptides: an update on bioactivity, potential therapeutic use and implication in cardiovascular diseases. Am J Hypertens. 2008;21:733–41.CrossRefGoogle Scholar
  20. 20.
    Kook H, Itoh H, Choi BS, Sawada N, Doi K, Hwang TJ, Kim KK, Arai H, Baik YH, Nakao K. Physiological concentration of atrial natriuretic peptide induces endothelial regeneration in vitro. Am J Physiol Heart Circ Physiol. 2003;284:H1388–97.CrossRefGoogle Scholar
  21. 21.
    Molkentin JD. A friend within the heart: natriuretic peptide receptor signaling. J Clin Invest. 2003;111:1275–7.CrossRefGoogle Scholar
  22. 22.
    Calvieri C, Rubattu S, Volpe M. Molecular mechanisms underlying cardiac antihypertrophic and antifibrotic effects of natriuretic peptides. J Mol Med. 2012;90:5–13.CrossRefGoogle Scholar
  23. 23.
    Bordicchia M, Liu D, Amri EZ, Ailhaud G, Dessì-Fulgheri P, Zhang C, Takahashi N, Sarzani R, Collins S. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest. 2012;122:1022–36.CrossRefGoogle Scholar
  24. 24.
    John SW, Krege JH, Oliver PM, Hagaman JR, Hodgin JB, Pang SC, Flynn TG, Smithies O. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science. 1995;267:679–81.CrossRefGoogle Scholar
  25. 25.
    Oliver PM, Fox JE, Kim R, Rockman HA, Kim HS, Reddick RL, Pandey KN, Milgram SL, Smithies O, Maeda N. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci U S A. 1997;94:14730–5.CrossRefGoogle Scholar
  26. 26.
    Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, Suda M, Kasahara M, Hashimoto R, Katsuura G, Mukoyama M, Itoh H, Saito Y, Tanaka I, Otani H, Katsuki M. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A. 2000;97:4239–44.CrossRefGoogle Scholar
  27. 27.
    Chusho H, Tamura N, Ogawa Y, Yasoda A, Suda M, Miyazawa T, Nakamura K, Nakao K, Kurihara T, Komatsu Y, Itoh H, Tanaka K, Saito Y, Katsuki M, Nakao K. Dwarfism and early death in mice lacking C-type natriuretic peptide. Proc Natl Acad Sci U S A. 2001;98:4016–21.CrossRefGoogle Scholar
  28. 28.
    Volpe M, Rubattu S, Burnett J Jr. Natriuretic peptides in cardiovascular diseases: current use and perspectives. Eur Heart J. 2014;35:419–25.CrossRefGoogle Scholar
  29. 29.
    Burnett JC Jr, Kao PC, Hu DC, Heser DW, Heublein D, Granger JP, Opgenorth TJ, Reeder GS. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science. 1986;231:1145–7.CrossRefGoogle Scholar
  30. 30.
    Mukoyama M, Nakao K, Saito Y, et al. Increased human brain natriuretic peptide in congestive heart failure. N Engl J Med. 1990;323:757–8.CrossRefGoogle Scholar
  31. 31.
    Ichiki T, Boerrigter G, Huntley BK, Sangaralingham SJ, McKie PM, Harty GJ, Harders GE, Burnett JC Jr. Differential expression of the pro-natriuretic peptide convertases corin and furin in experimental heart failure and atrial fibrosis. Am J Physiol Regul Integr Comp Physiol. 2013;304:R102–9.CrossRefGoogle Scholar
  32. 32.
    Ibebuogu UN, Gladysheva IP, Houng AK, Reed GL. Decompensated heart failure is associated with reduced corin levels and decreased cleavage of pro-atrial natriuretic peptide. Circ Heart Fail. 2011;4:114–20.CrossRefGoogle Scholar
  33. 33.
    Gladysheva IP, Wang D, McNamee RA, Houng AK, Mohamad AA, Fan TM, Reed GL. Corin overexpression improves cardiac function, heart failure, and survival in mice with dilated cardiomyopathy. Hypertension. 2013;61:327–32.CrossRefGoogle Scholar
  34. 34.
    Miller WL, Phelps MA, Wood CM, Schellenberger U, Van Le A, Perichon R, Jaffe AS. Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure. Circ Heart Fail. 2011;4:355–60.CrossRefGoogle Scholar
  35. 35.
    Dickey DM, Dries DL, Margulies KB, Potter LR. Guanylyl cyclase (GC)-A and GC-B activities in ventricles and cardiomyocytes from failed and non-failed human hearts: GC-A is inactive in the failed cardiomyocyte. J Mol Cell Cardiol. 2012;52:727–32.CrossRefGoogle Scholar
  36. 36.
    Knecht M, Pagel I, Langenickel T, Philipp S, Scheuermann-Freestone M, Willnow T, Bruemmer D, Graf K, Dietz R, Willenbrock R. Increased expression of renal neutral endopeptidase in severe heart failure. Life Sci. 2002;71:2701–12.CrossRefGoogle Scholar
  37. 37.
    Margulies KB, Burnett JC Jr. Inhibition of cyclic GMP phosphodiesterases augments renal responses to atrial natriuretic factor in congestive heart failure. J Card Fail. 1994;1:71–80.CrossRefGoogle Scholar
  38. 38.
    Cameron VA, Aitken GD, Ellmers LJ, Kennedy MA, Espiner EA. The sites of gene expression of atrial, brain, and C-type natriuretic peptides in mouse fetal development: temporal changes in embryos and placenta. Endocrinology. 1996;137:817–24.CrossRefGoogle Scholar
  39. 39.
    Larsen TH, Saetersdal T. Regional appearance of atrial natriuretic peptide in the ventricles of infarcted rat hearts. Virchows Arch B Cell Pathol Incl Mol Pathol. 1993;64:309–14.CrossRefGoogle Scholar
  40. 40.
    Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA, Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161–7.CrossRefGoogle Scholar
  41. 41.
    Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891–975.CrossRefGoogle Scholar
  42. 42.
    Felker GM, Anstrom KJ, Adams KF, Ezekowitz JA, Fiuzat M, Houston-Miller N, Januzzi JL Jr, Mark DB, Piña IL, Passmore G, Whellan DJ, Yang H, Cooper LS, Leifer ES, Desvigne-Nickens P, O’Connor CM. Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2017;318:713–20.CrossRefGoogle Scholar
  43. 43.
    Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:1810–52.CrossRefGoogle Scholar
  44. 44.
    Seronde MF, Gayat E, Logeart D, Lassus J, Laribi S, Boukef R, Sibellas F, Launay JM, Manivet P, Sadoune M, Nouira S, Solal AC, Mebazaa A. Comparison of the diagnostic and prognostic values of B-type and atrial-type natriuretic peptides in acute heart failure. Int J Cardiol. 2013;168:3404–11.CrossRefGoogle Scholar
  45. 45.
    Masson S, Latini R, Anand IS, Barlera S, Angelici L, Vago T, Tognoni G, Cohn JN. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol. 2008;52:997–1003.CrossRefGoogle Scholar
  46. 46.
    de Lemos JA, McGuire DK, Khera A, Das SR, Murphy SA, Omland T, Drazner MH. Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study. Am Heart J. 2009;157:746–53.CrossRefGoogle Scholar
  47. 47.
    Nakamura M, Tanaka F, Onoda T, Takahashi T, Sakuma M, Kawamura K, Tanno K, Ohsawa M, Itai K, Sakata K, Makita S, Iwate KENCO Study Groups. Gender-specific risk stratification with plasma B-type natriuretic peptide for future onset of congestive heart failure and mortality in the Japanese general population. Int J Cardiol. 2010;143:124–9.CrossRefGoogle Scholar
  48. 48.
    Ledwidge M, Gallagher J, Conlon C, Tallon E, O’Connell E, Dawkins I, Watson C, O’Hanlon R, Bermingham M, Patle A, Badabhagni MR, Murtagh G, Voon V, Tilson L, Barry M, McDonald L, Maurer B, McDonald K. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA. 2013;310:66–74.CrossRefGoogle Scholar
  49. 49.
    Willeit P, Kaptoge S, Welsh P, Butterworth AS, Chowdhury R, Spackman MMath SA, Pennells L, Gao P, Burgess S, Freitag DF, Sweeting M, Wood AM, Cook NR, Judd S, Trompet S, Nambi V, Hecht Olsen H, Everett BM, Kee F, Ärnlöv J, Salomaa V, Levy D, Kauhanen J, Laukkanen JA, Kavousi M, Ninomiya T, Casas JP, Daniels LB, Lind L, Kistorp CN, Rosenberg J, Mueller T, Rubattu S, Panagiotakos DB, Franco OH, de Lemos JA, Luchner A, Kizer JR, Kiechl S, Salonen JT, Wannamethee G, de Boer RA, Nordestgaard BG, Andersson J, Jørgensen T, Melander O, Ballantyne CM, DeFilippi C, Ridker PM, Cushman M, Rosamond WD, Thompson SG, Gudnason V, Sattar N, Danesh J, Di Angelantonio E. Natriuretic peptides and integrated risk assessment for cardiovascular disease: individual-participant data meta-analysis of 40 prospective studies. Lancet Diabetes Endocrinol. 2016;4:840–9.CrossRefGoogle Scholar
  50. 50.
    Ichiki T, Burnett J Jr. Atrial natriuretic peptide. Old but new therapeutic in cardiovascular diseases. Circ J. 2017;81:913–9.CrossRefGoogle Scholar
  51. 51.
    Gong B, Wu Z, Li Z. Efficacy and safety of nesiritide in patients with decompensated heart failure: a meta-analysis of randomised trials. BMJ Open. 2016;6:e008545.CrossRefGoogle Scholar
  52. 52.
    Packer M, O’Connor C, McMurray JJV, Wittes J, Abraham WT, Anker SD, Dickstein K, Filippatos G, Holcomb R, Krum H, Maggioni AP, Mebazaa A, Peacock WF, Petrie MC, Ponikowski P, Ruschitzka F, van Veldhuisen DJ, Kowarski LS, Schactman M, Holzmeister J, Investigators TRUE-AHF. Effect of ularitide on cardiovascular mortality in acute heart failure. N Engl J Med. 2017;376:1956–64.CrossRefGoogle Scholar
  53. 53.
    Nomura F, Kurobe N, Mori Y, Hikita A, Kawai M, Suwa M, Okutani Y. Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: Carperitide effects observed through monitoring dyspnea in acute decompensated heart failure study. Circ J. 2008;72:1777–86.CrossRefGoogle Scholar
  54. 54.
    Rose RA. CD-NP, a chimeric natriuretic peptide for the treatment of heart failure. Curr Opin Investig Drugs. 2010;11:349–56.PubMedGoogle Scholar
  55. 55.
    Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, Swedberg K. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106:920–6.CrossRefGoogle Scholar
  56. 56.
    McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.CrossRefGoogle Scholar
  57. 57.
    Volpe M, Tocci G, Battistoni A, Rubattu S. Angiotensin II receptor blocker nephrilysin inhibitor (ARNI): new avenues in cardiovascular therapy. High Blood Press Cardiovasc Prev. 2015;22:241–6.CrossRefGoogle Scholar
  58. 58.
    Dickey DM, Yoder AR, Potter LR. A familial mutation renders atrial natriuretic peptide resistant to proteolytic degradation. J Biol Chem. 2009;284:19196–202.CrossRefGoogle Scholar
  59. 59.
    Arora P, Wu C, Khan AM, Bloch DB, Davis-Dusenbery BN, Ghorbani A, Spagnolli E, Martinez A, Ryan A, Tainsh LT, Kim S, Rong J, Huan T, Freedman JE, Levy D, Miller KK, Hata A, Del Monte F, Vandenwijngaert S, Swinnen M, Janssens S, Holmes TM, Buys ES, Bloch KD, Newton-Cheh C, Wang TJ. Atrial natriuretic peptide is negatively regulated by microRNA-425. J Clin Invest. 2013;123:3378–82.CrossRefGoogle Scholar
  60. 60.
    Wu C, Arora P, Agha O, Hurst LA, Allen K, Nathan DI, Hu D, Jiramongkolchai P, Smith JG, Melander O, Trenson S, Janssens SP, Domian I, Wang TJ, Bloch KD, Buys ES, Bloch DB, Newton-Cheh C. Novel microRNA regulators of atrial natriuretic peptide production. Mol Cell Biol. 2016;36:1977–87.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Clinical and Molecular Medicine, School of Medicine and PsychologySapienza University of RomeRomeItaly
  2. 2.IRCCS NeuromedPozzilliItaly

Personalised recommendations